Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Arecor, the company on Chesterton Research Park developing better treatments for diabetes, has been awarded a £1.05m government grant to help push ahead to early stage clinical trials.
The biotech company is reformulating proteins and peptides to improvement treatment for other ills as well as diabetes.
Arecor’s liquid glucagon is an important addition to its speciality diabetes pipeline and will offer a vastly superior glucagon rescue treatment for severe hypoglycaemia and may have further applications in enabling dual hormone artificial pancreas systems.
Glucagon is a life-saving emergency treatment used to treat dangerously low blood glucose levels known as severe hypoglycaemia.
http://www.cambridge-news.co.uk/business/business-news/105m-grant-cambridge-diabetes-firm-12551224
Very good news 🙂
The biotech company is reformulating proteins and peptides to improvement treatment for other ills as well as diabetes.
Arecor’s liquid glucagon is an important addition to its speciality diabetes pipeline and will offer a vastly superior glucagon rescue treatment for severe hypoglycaemia and may have further applications in enabling dual hormone artificial pancreas systems.
Glucagon is a life-saving emergency treatment used to treat dangerously low blood glucose levels known as severe hypoglycaemia.
http://www.cambridge-news.co.uk/business/business-news/105m-grant-cambridge-diabetes-firm-12551224
Very good news 🙂
